 |
Dr. David Karabelnik CEO, Private Equity/Life Sciences Zürich • 12 Years of International VC and PE Experience • Breslin Biotech: Building of BdW-Dresdner-Allianz Life Sciences Portfolio • Life Sciences Advisor to Commerzbank and Deutsche Bank • VC&Biotech S.Francisco • 12 years Biotech Entrepreneur at ANAWA (Founder and Managing Director) • Ph.D. and Masters in Biochemistry (ETH Zurich) |
 |
Malcolm Williams Private Equity London • 38 Years of Private Equity Experience at Dresdner Kleinwort Wasserstein • COO of Dresdner-Allianz Private Equity Group (>Euro 4bn under Mgmt of Direct and Fund Investm.) • CEO of Kleinwort Benson Limited, Hong Kong • Member of the Mgmt Board of Kleinwort Benson, Germany |
 |
Klaus Berding Life Sciences/Private Equity Frankfurt • 4 Years as Management Consultant in Life Sciences • 7 Years VP Corporate Finance at Dresdner Kleinwort Wasserstein • 6 Years as Senior Analyst in Sell-Side Research at Dresdner Bank AG • Diploma and Seminars: DVFA Investmentanalyst, Venture Capital (EVCA), Business Development • MBA (University Bochum) |
 |
Dr. Martin Schnee Industrial- and Clean-Tech/Life Sciences Frankfurt • 7 Years Independent Analyst Chemistry ,Life Sciences • 1 Year Sector Analyst with Euroratings AG • 2 Years Sector Analyst in Sell-Side with Independent Research • Certified Biotech Analyst and Certified Credit Analyst (DVFA) PhD in Chemistry (Frankfurt University) |
 |
Fanina Karabelnik |
